SciVision Biotech Inc
TWSE:1786

Watchlist Manager
SciVision Biotech Inc Logo
SciVision Biotech Inc
TWSE:1786
Watchlist
Price: 90.7 TWD -1.41% Market Closed
Market Cap: 6.4B TWD
Have any thoughts about
SciVision Biotech Inc?
Write Note

SciVision Biotech Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SciVision Biotech Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
SciVision Biotech Inc
TWSE:1786
Cash & Cash Equivalents
NT$568.8m
CAGR 3-Years
-6%
CAGR 5-Years
20%
CAGR 10-Years
8%
M
Medtecs International Corporation Ltd
SGX:546
Cash & Cash Equivalents
$17.6m
CAGR 3-Years
-34%
CAGR 5-Years
58%
CAGR 10-Years
22%
V
Visco Vision Inc
TWSE:6782
Cash & Cash Equivalents
NT$520.8m
CAGR 3-Years
30%
CAGR 5-Years
27%
CAGR 10-Years
N/A
P
Pegavision Corp
TWSE:6491
Cash & Cash Equivalents
NT$1.1B
CAGR 3-Years
-15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
OK Biotech Co Ltd
TWSE:4155
Cash & Cash Equivalents
NT$360.6m
CAGR 3-Years
-16%
CAGR 5-Years
35%
CAGR 10-Years
N/A
No Stocks Found

SciVision Biotech Inc
Glance View

Market Cap
6.4B TWD
Industry
Health Care

SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.

Intrinsic Value
178.54 TWD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is SciVision Biotech Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
568.8m TWD

Based on the financial report for Sep 30, 2024, SciVision Biotech Inc's Cash & Cash Equivalents amounts to 568.8m TWD.

What is SciVision Biotech Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
8%

Over the last year, the Cash & Cash Equivalents growth was -15%. The average annual Cash & Cash Equivalents growth rates for SciVision Biotech Inc have been -6% over the past three years , 20% over the past five years , and 8% over the past ten years .

Back to Top